Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07039474 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Dec 31, 2026 → Dec 1, 2028
Primary endpoints added 4 → 7 primary endpoints
See other at-risk trials from Peking University First Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Dec 1, 2028 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Recruitment opened
    • Start date changed from estimate of Jul 15, 2025 to Sep 8, 2026
    • Study completion pushed from Jun 1, 2027 to Dec 15, 2028
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Peking University First Hospital
199 trials monitored
See 10 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
and 2 more diseases
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
Trial Details
NCT Number NCT07039474
Lead Sponsor Peking University First Hospital
Conditions
(from sponsor)		 Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Lymphoma
Related terms Breast Neoplasms, Esophageal Neoplasms, Hematologic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Stomach Neoplasms
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov